摩贝百科
诺力昂助剂 佐敦工业漆 老虎粉末涂料 原料抢购 聚合氯化铝 聚丙烯酰胺 无水氯化钙 9-氯甲基蒽
结构式
官能团
首页 > 化工百科 > 生物及医药化学品 > 医药原料药 > 孤儿药 > 2-(3,5-二氯苯基)-6-苯并恶唑甲酸
594839-88-0 2-(3,5-二氯苯基)-6-苯并恶唑甲酸

2-(3,5-二氯苯基)-6-苯并恶唑甲酸
英文名称：tafamidis
CAS：

594839-88-0

 分子式：C14H7Cl2NO3
精选商品
相关知识
概览
  • 化合物简介
  • 基本信息
  • 编号系统
  • 物化性质
  • 合成路线
  • MSDS
  • 图谱
  • 上游原料

2-(3,5-二氯苯基)-6-苯并恶唑甲酸简介

Tafamidis (INN, or Fx-1006A, trade name Vyndaqel) is a drug for the amelioration of transthyretin-related hereditary amyloidosis (also familial amyloid polyneuropathy, or FAP), a rare but deadly neurodegenerative disease. The drug was approved by the European Medicines Agency in November 2011 and by the Japanese Pharmaceuticals and Medical Devices Agency in September 2013.
The marketed drug, a meglumine salt, has completed an 18 month placebo controlled phase II/III clinical trial, and an 12 month extension study which provides evidence that tafamidis slows progression of Familial amyloid polyneuropathy. Tafamidis (20mg once daily) is used in adult patients with an early stage (stage 1) of familial amyloidotic polyneuropathy.
Tafamidis was discovered in the Jeffery W. Kelly Laboratory at The Scripps Research Institute using a structure-based drug design strategy and was developed at FoldRx pharmaceuticals, a biotechnology company Kelly co-founded with Susan Lindquist. FoldRx was led by Richard Labaudiniere when it was acquired by Pfizer in 2010.
Tafamidis functions by kinetic stabilization of the correctly folded tetrameric form of the transthyretin (TTR) protein. In patients with FAP, this protein dissociates in a process that is rate limiting for aggregation including amyloid fibril formation, causing failure of the autonomic nervous system and/or the peripheral nervous system (neurodegeneration) initially and later failure of the heart. Kinetic Stabilization of tetrameric transthyretin in familial amyloid polyneuropathy patients provides the first pharmacologic evidence that the process of amyloid fibril formation causes this disease, as treatment with tafamidis dramatically slows the process of amyloid fibril formation and the degeneration of post-mitotic tissue. Sixty% of the patients enrolled in the initial clinical trial have the same or an improved neurologic impairment score after six years of taking tafamidis, whereas 30% of the patients progress at a rate ≤ 1/5 of that predicted by the natural history. Importantly, all of the V30M FAP patients remain stage 1 patients after 6 years on tafamidis out of four stages of disease progression. [Data presented orally by Professor Coelho in Brazil in 2013]
The process of wild type transthyretin amyloidogenesis also appears to cause senile systemic amyloidosis leading to cardiomyopathy as the prominent phenotype Some mutants of transthyretin, including V122I primarily found in individuals of African descent, are destabilizing enabling heterotetramer dissociation, monomer misfolding, and subsequent misassembly of transthyretin into a variety of aggregate structures including amyloid fibrils leading to familial amyloid cardiomyopathy. While there is clinical evidence from a small number of patients that tafamidis slows the progression of the transthyretin cardiomyopathies, this has yet to be demonstrated in a placebo controlled clinical trial. Pfizer has enrolled a placebo-controlled clinical trial to evaluate the ability of tafamidis to slow the progression of familial amyloid cardiomyopathy (mutant and wild type TTR aggregation) and senile systemic amyloidosis, a cardiomyopathy caused by the aggregation of wild type TTR (ClinicalTrials.gov identifier: NCT01994889).

2-(3,5-二氯苯基)-6-苯并恶唑甲酸基本信息

中文名称 2-(3,5-二氯苯基)-6-苯并恶唑甲酸 英文名称 tafamidis
中文别名

2-(3,5-二氯苯基)-6-苯并噁唑羧酸;

查看更多中文别名 		英文别名

8FG9H9D31J; TAFAMIDIS; 2-(3,5-Dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid; UNII-8FG9H9D31J; FX-1006; 3MI;

查看更多英文别名
CAS号 594839-88-0 分子式 C14H7Cl2NO3
分子量 308.11600 精确质量 306.98000
PSA 63.33000 LOGP 4.49980

2-(3,5-二氯苯基)-6-苯并恶唑甲酸编号系统

UNII 8FG9H9D31J

2-(3,5-二氯苯基)-6-苯并恶唑甲酸物化性质

密度：
1.53
查看详情 >
查看更多
SDS 1.0 中文 展开
SDS 1.0 英文 展开
1H NMR : Predict展开

核磁图谱 1H NMR : Predict

收起
查看更多

2-(3,5-二氯苯基)-6-苯并恶唑甲酸上游原料

共找到4个上游原料
查看更多上游原料 >
您可能感兴趣的化合物
快捷导航
生物及医药化学品 医药原料药 孤儿药
上游原料
3,5-二氯苯甲酰氯 4-氨基-3-羟基苯甲酸 4-(6-benzoxazoyl)morpholine 1,3-苯并恶唑-6-羧酸
594839-88-0 2-(3,5-二氯苯基)-6-苯并恶唑甲酸
2-(3,5-二氯苯基)-6-苯并恶唑甲酸
CAS号：594839-88-0 分子式：C14H7Cl2NO3 分子量：308.11600
查看供应商 立即选购

化工圈APP

二维码

微信公众号

二维码
关于我们 商务合作 厂家库 产品库 摩贝百科 摩贝行情 移动站 联系我们 法律声明 营业执照 帮助中心 投资者关系
Copyright © 2013-2024 MOLBASE All Rights Reserved 上海摩企数据技术有限公司
沪公网安备 31010402005161号 | 沪ICP备2024066981号-2 | 增值电信业务经营许可证： 沪B2-20140080

购物车

不要让您的购物车空着哦，买试剂、买原料
如果您已添加过宝贝，那就赶紧登录查看吧

获取报价

已选 清空
等0家供应商
  • 商品名称
  • CAS号
  • 采购数量*
  • 单位*
  • 纯度
  • 联系人
  • 联系人手机*
  • 需求时效*
  • 收货地址*
  •  
  • 公司/单位*
  • 备注
  • 手机号码必须为11位数字！
    立即提交

投诉建议

  • 咨询类别
  • 问题描述
  • 联系人电话
  • 联系人
  • 手机号码必须为11位数字！